IRulya Therapeutics Inc.
corporate_fare Company Profile
IRulya Therapeutics Inc. (NASDAQ:IRLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for IRLA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for IRLA spans 10-Q.
Recent high-impact activity:
- IRulya Q3 Loss Widens to $27.7M on Warrant Mark; $105.2M Cash Funds 12 Months
- IRulya Posts $27.7M Q3 Loss, Says $105.2M Cash Funds Operations Through 2028
Financial Snapshot
Short Interest & Short Volume
1.13 days to coverFINRA reported short interest of 127,816 shares in IRLA as of the October 30, 2026 settlement, a 17.4% decrease from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 62.2% of IRLA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IRLA, detected from its recent SEC filings.
S-3 Amendment Filed · Resale Registration Details
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →